Status:
COMPLETED
Stratification for F-L Therapy After LT
Lead Sponsor:
Xiao Xu
Conditions:
Liver Transplantation
Adjuvant FOLFOX Plus Lenvatinib
Eligibility:
All Genders
18-70 years
Brief Summary
Objective: To stratify recipients who underwent adjuvant FOLFOX plus lenvatinib (F-L) therapy following liver transplantation (LT) for hepatocellular carcinoma and provide guidance for clinical adjuva...
Eligibility Criteria
Inclusion
- patients fulfilling the Hangzhou criteria or exceeding the Hangzhou criteria with type 1 or 2 portal vein tumor thrombus (PVTT) before LT
Exclusion
- 1\) individuals less than 18 years old; 2) individuals with malignancies other than HCC; 3) individuals who survived less than 30 days after LT; and 4) individuals who lacked important prognostic variables, such as contrast-enhanced CT imaging information one month before transplantation, preoperative alpha-fetoprotein (AFP) levels, and tumor differentiation data
Key Trial Info
Start Date :
January 1 2024
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
August 5 2024
Estimated Enrollment :
1 Patients enrolled
Trial Details
Trial ID
NCT06564103
Start Date
January 1 2024
End Date
August 5 2024
Last Update
August 21 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Zhejiang University school of Medicine
Hangzhou, Zhejiang, China, 310000